Critical Questions in Choosing EGFR-Targeted Therapies for NSCLC - Episode 2

FLAURA, FLAURA2, and MARIPOSA: Key Takeaways to Impact First-Line Treatment Approach

,

Panelists discuss how the FLAURA, FLAURA2, and MARIPOSA trials have reshaped first-line therapy for EGFR-mutant non–small cell lung cancer. FLAURA established osimertinib as superior to first-generation tyrosine kinase inhibitors. FLAURA2 showed added benefit with chemotherapy. MARIPOSA highlighted amivantamab-lazertinib as a strong alternative, refining treatment choices.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Brief Overview of the Treatment Landscape of First-Line EGFRm NSCLC
    Now Viewing
    EP. 2: FLAURA, FLAURA2, and MARIPOSA: Key Takeaways to Impact First-Line Treatment Approach
    EP. 3: Clinical Factors to Consider When Choosing a Treatment Strategy
    EP. 4: Treatment Strategies to Manage AEs in EGFRm NSCLC

    Video content above is prompted by the following:

    • Can you walk us through how the FLAURA, FLAURA2, and MARIPOSA data have influenced your approach to first-line therapy? What aspects of these trials were most compelling?
      • FLAURA: Ramalingam SS, et al. ESMO 2019. Abstract LBA5_PR. J. Soria, FLAURA_NEJM_2017,
      • FLAURA2: D. Planchard, FLAURA2_NEJM_2023
      • MARIPOSA: M. Campelo ESMO 2024 Abstract 5M0, E. Felip ASCO 2024 Abstract 8504
    x